In contrast, canakinumab was associated with a higher prevalence of abnormal investigations including C-reactive protein increased, gastrointestinal disorders including abdominal pain, mouth ulceration, and inflammatory bowel disease, and respiratory disorders including cough, oropharyngeal pain, and rhinorrhoea. The gene discussed is CRP; the disease is inflammatory bowel disease.